Comments on “A bold vision for America’s mental well being” Richard G. Frank and Sherry Glied Tuesday, October 19, 2021
Paying for cancer drugs that prove their benefit Richard G. Frank and Ezekiel Emanuel Thursday, October 14, 2021
From vision to design in advancing Medicare payment reform J. Michael McWilliams, Alice Chen, and Michael E. Chernew Wednesday, October 13, 2021
Private equity investment as a divining rod for market failure: Policy responses to harmful physician practice acquisitions Erin C. Fuse Brown, Loren Adler, Erin Duffy, Paul B. Ginsburg, Mark Hall, and Samuel Valdez Tuesday, October 5, 2021
Changes in emergency physician service prices after Connecticut’s 2016 surprise billing law Loren Adler, Erin Duffy, Bich Ly, Conrad Milhaupt, and Erin Trish Thursday, September 23, 2021
Options for containing the cost of a new Medicare dental, hearing, and vision benefit Matthew Fiedler Friday, September 10, 2021
Comments on No Surprises Act Rulemaking: Part I Loren Adler, Matthew Fiedler, and Benedic Ippolito Wednesday, September 1, 2021
A framework for categorizing and analyzing prescription drug pricing reform options Rachel Sachs, Loren Adler, and Paul B. Ginsburg Tuesday, August 31, 2021
Government regulated or negotiated drug prices: Key design considerations Paul B. Ginsburg and Steven M. Lieberman Monday, August 30, 2021
